GlassScriptPhysician profile
Rumon Chakravarty
NPI 1982982856
$21,836.26
in general payments reported to CMS, 2019-2025
14 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2022: $287 · 2023: $464 · 2024: $5,153 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $2,189 · Travel and Lodging: $1,781 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,220.00 |
| Food and Beverage | $2,188.92 |
| Travel and Lodging | $1,781.45 |
| Education | $197.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19,193.33 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Becton, Dickinson and Company | $1,278.76 | 2024 | |
| Edwards Lifesciences Corporation | $442.96 | 2024 | |
| United Therapeutics Corporation | $222.40 | 2024-2025 | Orenitram, Remodulin |
| Getinge USA Sales, LLC | $216.06 | 2022-2023 | Cardiohelp |
| Abbott Laboratories | $195.55 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Grifols USA, LLC | $110.21 | 2019 | |
| Inari Medical, INC. | $40.72 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Regeneron Pharmaceuticals, INC. | $39.77 | 2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $28.85 | 2025 | Onpattro |
| Glaxosmithkline, LLC. | $24.98 | 2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $24.25 | 2024 | Camzyos |
| Philips North America LLC | $18.42 | 2025 | Vest Therapy Und |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rumon Chakravarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.